Founders Fund Growth Management’s AbCellera Biologics ABCL Stock Holding History

Founders Fund Growth Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-407,017	Closed	-$1.2M	–	3
2024 Q2	$1.2M	Hold	407,017	–	–	3.68%	2
2024 Q1	$1.84M	Hold	407,017	–	–	2.94%	2
2023 Q4	$2.32M	Hold	407,017	–	–	2.81%	2
2023 Q3	$1.87M	Hold	407,017	–	–	5.1%	2
2023 Q2	$2.63M	Hold	407,017	–	–	9.39%	2
2023 Q1	$3.07M	Hold	407,017	–	–	14.23%	2
2022 Q4	$4.12M	Hold	407,017	–	–	20.66%	2
2022 Q3	$4.03M	Hold	407,017	–	–	11.55%	2
2022 Q2	$4.33M	Hold	407,017	–	–	12.66%	2
2022 Q1	$3.97M	Hold	407,017	–	–	4.48%	3
2021 Q4	$5.82M	Buy	+407,017	New	+$6.18M	3.28%	3

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Founders Fund Growth Management's ABCL Position: Q3 2024 in Review

Founders Fund Growth Management sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 407,017 shares — an estimated $1.2M sold.

Founders Fund Growth Management first reported a position in ABCL in Q4 2021 and held it in 11 quarters. The position peaked at $5.82M in Q4 2021. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

Founders Fund Growth Management reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
Founders Fund Growth Management sold 407,017 AbCellera Biologics shares in Q3 2024, an estimated $1.2M.
Founders Fund Growth Management first reported a position in AbCellera Biologics in Q4 2021 and held it in 11 quarters.
Founders Fund Growth Management's AbCellera Biologics position peaked at $5.82M in Q4 2021.
139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Founders Fund Growth Management's 13F filing for Q3 2024, filed 14 Nov 2024.